宋智

[摘要] 目的 探讨依达拉奉联合低分子肝素钙治疗进展型脑梗死的临床效果。 方法 将142例进展型脑梗死患者随机分为观察组和对照组，各71例，两组患者均给予常规对症治疗，对照组加用依达拉奉治疗，观察组加用依达拉奉联合低分子肝素钙治疗，观察两组患者的临床效果。 结果 观察组患者治疗后的NIHSS评分明显低于对照组（P<0.05），基本治愈率及总有效率分别为36.62%、90.14%，均明显高于对照组的11.27%、69.01%（P<0.05）。 结论 依达拉奉联合低分子肝素钙治疗进展型脑梗死具有效果好、神经功能改善明显等优点，且安全性较好。

[关键词] 进展性脑梗死；依达拉奉；低分子肝素钙；神经功能

[中图分类号] R743.9 [文献标识码] A [文章编号] 1674-4721（2014）04（a）-0077-03

[Abstract] Objective To discuss the clinical effect of edaravone combined with low molecular heparin calcium treating progressive cerebral infarction. Methods 142 patients with progressive cerebral infarction were equally divided into the observation and the control groups.Both groups received conventional symptomatic treatment，and the control group was additionally provided with edaravone，while the observation group was offered edaravone combined with low molecular heparin calcium.The treatment effect of patients in the two groups was observed. Results NIHSS score in the observation group was visibly lower than that in the control group after treatment （P<0.05），the basic cure rate and the total effective rate in the observation group （36.62%，90.14% respectively） was obviously higher than that in the control group （11.27%，69.01% respectively） （P<0.05）. Conclusion Edaravone combined with low molecular heparin calcium treating progressive cerebral has advantages of good effect，obvious improvement of neurological etc with good safely.

[Key words] Progressive cerebral infarction；Edaravone；Low molecular heparin calcium；Neurological function

进展型脑梗死是急性脑梗死中较为常见的一种亚型，是指在发病时神经功能缺损较轻，但呈进行性加重趋势，直至出现严重神经功能缺损，此病具有病死率高、致残率高等特点，属临床难治性脑梗死之一。有关调查显示，进展型脑梗死的发生率占全部脑梗死的26%～43%[1]，因此，寻求一种合理、有效的治疗方案对改善进展型脑梗死预后有重要意义。笔者近年来在常规治疗的基础上加用依达拉奉联合低分子肝素钙治疗进展型脑梗死，临床疗效满意。

1 资料与方法

1.1 一般资料

选取2012年12月～2013年12月本科收治的142例进展型脑梗死患者为本次研究对象，全部患者均经头颅CT或MRI检查确诊为脑梗死，发病6 h～7 d神经功能缺损呈进行性加重，经实验室检查凝血功能及血小板计数均在正常范围内，符合第四届脑血管病学术会议制订的相关诊断标准[2]。采取随机数字表法，将患者随机分为观察组和对照组，观察组71例：男36例，女35例；年龄41～73岁，平均（58.32±5.31）岁。对照组71例：男37例，女34例；……